Avalon GloboCare Corp. (ALBT) is an innovative, global biotechnology company dedicated to enhancing patient care by improving cellular and regenerative medicine. This cutting-edge health tech company is headquartered in Freehold, New Jersey, though its reach and impact are truly worldwide.
As a leading life sciences company, Avalon GloboCare is primarily engaged in the development and commercialization of a variety of transformative, disruptive healthcare technologies and therapeutics. It focuses on two primary areas: cellular immunotherapy and exosome-based technology. Their mission aims to enhance cell-based technologies to improve global health and redefine standards of care in treatment and disease prevention.
While it spans multiple disciplines, Avalon GloboCare’s core commitment always remains the same: to improve patient lives. With their strategically organized, globally focused operations, they've established manageable, dynamic pipelines of cellular therapeutics and innovative technologies that target critical life-threatening diseases and conditions.
Avalon's cellular immunotherapy division features CAR-T therapy and precision cellular immunotherapy which can be a possible therapeutic solution to not only alleviate symptoms but also treat numerous diseases like cancer. The company's exosome technology division, on the other hand, uses the body's naturally occurring nanocarriers to help in disease diagnostics and therapeutics.
Avalon GloboCare’s subsidiary, GenExosome Technologies Inc., has further expanded the company’s potential by developing next-generation diagnosis and treatment for diseases like cancer using their exosome-based technology. This novel approach offers the possibility of more advanced, personalized diagnostics and treatments by targeting the molecular and cellular setting of a patient’s disease.
One of the company's groundbreaking advancements is proprietary technology AVA-001, an automated and closed CAR-T cell production system that expedites patient access to life-saving cellular immunotherapies. They're also actively involved in developing COVID-19-related diagnostics, therapeutics, and vaccines.
With impeccable leadership from a clinical, scientific, and strategic standpoint, Avalon GloboCare is set to achieve significant progress in technology innovation and clinical translation. The company is dedicated to boosting societal health outcomes and fostering a healthier future for all name, using scientific advancements as their vehicle. This commitment, along with their disruptive technologies, positions Avalon GloboCare Corp. (ALBT) as a pioneering major player in the global biotech landscape.